Oral pharmacotherapy of childhood movement disorders

Journal of Child Neurology

Volumn 18, Issue SUPPL. 1, 2003, Pages

  Edgar, Terence S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BACLOFEN; BENZODIAZEPINE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLONIDINE; CORTICOSTEROID; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; GUANFACINE; HALOPERIDOL; IMMUNOGLOBULIN; LEVODOPA; NEUROLEPTIC AGENT; NIFEDIPINE; PHENYTOIN; PHYSOSTIGMINE; PILOCARPINE; PIMOZIDE; QUININE; RESERPINE; RISPERIDONE; TETRABENAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VERAPAMIL;

ANOREXIA; ATHETOSIS; BODY POSTURE; CARDIOTOXICITY; CHILD; CHOREA; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DRUG USE; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERKINESIA; INSOMNIA; MOTOR DYSFUNCTION; MOVEMENT (PHYSIOLOGY); MUSCLE HYPOTONIA; MUSCLE TONE; NEUROLOGIC DISEASE; ONSET AGE; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; TIC; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0042383445     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073803018001s0601     Document Type: Review

References (59)

1. Jankovic J: Phenomenology and classification of tics. Neurol Clin North Am 1997;15:267-275.
2. Hagberg G, Zetterstrom R: Decreasing perinatal mortality. Increase in cerebral palsy morbidity. Acta Paediatr Scand 1989;78:664-670.
3. Aicardi J, Bax M: Cerebral palsy, in Aicardi J (ed): Diseases of the Nervous System in Childhood, 2nd ed. London, MacKeith Press, 1998, 210-239.
4. Polani PE: The natural history of choreoathetoid cerebral palsy. Guy Hosp Rep 1959;108-132.
5. Burke RE, Fahn S, Gold AP: Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry 1980;43:93-104.
6. Young AB, Penney JB: Biochemical and functional organization of the basal ganglia, in Jankovic J, Tolosa E (eds): Parkinson's Disease and Movement Disorders, 3rd ed. Baltimore, Williams and Wilkins, 1998, 1-13.
7. Cavada C, Goldman-Rakic PS: Topographic segregation of cortico-striatal projection from posterior parietal subdivisions in the macaque monkey. Neuroscience 1991;42:683-696.
8. Alexander GE, Crutcher MD: Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
9. Carpenter MB, Whittier JR, Mettler FA: Analysis of choreoid hyperkinesias in the rhesus monkey. Surgical and pharmacological analysis of hyperkinesias resulting from lesions in the subthalamic nucleus of Lys. J Comp Neurol 1950;92:293-332.
10. Green LN: Corticosteroids in the treatment of Syndenham's chorea. Arch Neurol 1978;35-53.
11. Blunt SB, Brooks DJ, Kennard C: Steroid-responsive chorea in childhood following cardiac transplantation. Mov Disord 1994;9: 112-113.
12. Jankovic J, Beach J: Long term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
13. Daoud AS, Zaki M, Shakir R, et al: Effectiveness of sodium valproate in the treatment of Sydenham's chorea. Neurology 1990;40: 1140-1141.
14. Sethi KD, Patel BP: Inconsistent response to divalproex sodium in hemichorea/hemiballism. Neurology 1990;40:1630-1631.
15. Hallett M, Toro C: Dystonia and the supplementary sensorimotor area. Adv Neuvol 1996;70:471-476.
16. Lang AE: High dose anticholinergic therapy in adult dystonia. Can J Neurol Sci 1986;13:42-46.
17. Brans JW, Lindeboom R, Snoek JW, et al: Botulinum toxin versus trihexphenidyl in cervical dystonia: A prospective randomized, double-blind controlled trial. Neurology 1996;46:1066-1072.
18. Greene O, Shale H, Fahn S: Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988;3:46-60.
19. Jankovic J: Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study. Ann Neurol 1982;11: 41-47.
20. Marsden CD, Marion MH, Quinn N: The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984;47:1166-1173.
21. Weiner WJ, Lang AE (eds): Movement Disorders. A Comprehensive Survey. Mount Kisko, NY, Futura, 1989.
22. Green P, Fahn S: Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 1992;7:48-52.
23. Marsden CD: Paroxysmal choreoathetosis. Adv Neurol 1996;70: 467-470.
24. Hirsch E, Sella F, Maton B, et al: Nocturnal paroxysmal dystonia: A clinical form of focal epilepsy. Neurophysiol Clin 1994;24: 207-217.
25. Biary N, Singh B, Bahou Y, et al: Posttraumatic paroxysmal nocturnal hemidystonia. Mov Disord 1994;9:98-99.
26. Singer HS, Hahn IH, Moran TH: Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 1991;30:558-562.
27. Leckman JE, Detlar J, Harcherik DF, et al: Short and long-term treatment of Tourette's syndrome with clonidine. A clinical perspective. Neurology 1985;35:343-351.
28. Walkup JT, Scahill LD, Riddle MA: Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome, in Weiner WJ, Lang AE (eds): Advances in Neurology. Behavioural Neurology of Movement Disorders, vol. 65. New York, Raven Press, 1995, 259-272.
29. Erenberg G, Cruse RP, Rothner AD: The natural history of Tourette syndrome. A follow-up study. Ann Neurol 1987;22:383-385.
30. Chappell PB, Leckman JF, Riddle MA: The pharmacologic treatment of the tic disorders. Child Adolesc Psychiatr Clin North Am 1995;4:197-216.
31. Goetz CG, Klawans HN: Fluphenazine and multifocal tic disorders. Arch Neurol 1984;41:271-272.
32. Van der Linden C, Bruggerman R, Van Woerkom TC: Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: An open pilot dose titration study with risperidone. Mov Disord 1994;9: 687-688.
33. Sallee FR, Kurlan R, Goetz CG, et al: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 2000;39:292-299.
34. Gilbert DL, Sethuraman G, Sine L, et al: Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000;54:1310-1315.
35. Jankovic J, Beech J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362.
36. Obeso JA, Artieda J, Rothwell JC, et al: The treatment of severe action myoclonus. Brain 1989;112:765-777.
37. Obeso JA, Arteida J, Quinn NP, et al: Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11: 529-536.
38. Krauss GL, Bergin A, Kramer RE, et al: Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;56:411-412.
39. Kyllerman M, Ben-Menachem E: Zonisamide for progressive myoclonus epilepsy: Long-term observations in seven patients. Epilepsy Res 1998;29:109-114.
40. Pranzatelli MR: The pharmacology of myoclonus. Clin Neuropharmacol 1995;8:99-130.
41. Chokroverty S, Manocha MK, Duvoisin RC: A physiologic and pharmacologic study in anticholinergic-responsive essential myoclonus. Neurology 1987;37:608-615.
42. Elble RJ: Central mechanisms of tremor. J Clin Neurophysiol 1996; 13:133-144.
43. Koller WC, Royse VL: Efficacy of primidone in essential tremor. Neurology 1986;36:121-124.
44. Sasso E, Perucca E, Fava R, et al: Quantitative comparison of barbiturates in essential hand and head tremor. Mov Disord 1991;6: 304-309.
45. Conner GS: A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002;59:132-134.
46. Burns RS, Chiueh CC, Markey SP, et al: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4 phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983;80: 4546-4550.
47. Bergman H, Wichmann T, De Long MR: Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
48. Botez MI, Botez-Marquard T, Elie R, et al: Amantidine hydrochloride in heredodegenerative ataxia: A double blind study. J Neurol Neurosurg Psychiatry 1996;61:259-264.
49. Botez MI, Young SN, Rotez T, et al: Treatment of heredo-degenerative ataxias with amantadine hydrochloride. Can J Neurol Sci 1991;18:307-311.
50. Milla PJ, Jackson ADM: A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
51. Young RR, Enure M, Nance PW, et al: Current issues in spasticity management. Neurologist 1997;3:261-275.
52. Denhoff E: Cerebral palsy-A pharmacologic approach. Clin Pharmacol Ther 1964;5:947-954.
53. Nogen AG: Effect of dantrolene sodium on the incidence of seizures in children with spasticity. Childs Brain 1979;5:420-425.
54. Nance PW, Young RR: Antispasmodic medications. Phys Med Rehabil Clin North Am 1999;10:337-355.
55. Ford F, Bleck EE, Aptekar RG, et al: Efficacy of dantrolene sodium in the treatment of spastic cerebral palsy. Dev Med Child Neurol 1976;18:770-783.
56. Denhoff E, Feldman S, Smith MG, et al: Treatment of spastic cerebral-palsied children with dantrolene sodium. Dev Med Child Neurol 1975;17:736-742.
57. Halsam RHA, Walcher JR, Leitman PS, et al: Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974;55:384-388.
58. Gracies J-M, Nance P, Elovic E, et al: Traditional pharmacologic treatments for spasticity part II: General and regional treatments. Muscle Nerve 1997;20(Suppl 6):S92-S120.
59. Cutter NC, Scott DD, Johnson JC, Whiteneck G: Gabapentin effect on spasticity in muliple sclerosis. A placebo controlled randomized trial. Arch Phys Med Rehabil 2000;81:164-169.